About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Ovarian Cancer Clinical Trials in Massachusetts | 439 Studies

Clinical Trials Ovarian CancerMassachusetts

Ovarian Cancer Clinical Trials in Massachusetts

Find 439 clinical trials for ovarian cancer near Massachusetts. Connect with research centers in your area.

All Ovarian Cancer trials nationwide All trials in Massachusetts

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 241-260 of 439 trials

RecruitingSYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryInternational registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool…NCT03452774·Birmingham, Alabama and 67 others

Ovarian Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

TerminatedA Study of PF-06873600 in People With CancerThe purpose of this clinical trial is to learn about the safety and effects of study medicine (PF-06873600) when taken alone or with hormone therapy by people with cancer.NCT03519178·Birmingham, Alabama and 53 others

Active not recruitingStudy of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus NACT compared to NACT alone.NCT03393884·Birmingham, Alabama and 20 others

CompletedEnapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid TumorsThe purpose of the trial is to determine the maximum tolerated dose and to establish the safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid…NCT02988817·Phoenix, Arizona and 40 others

CompletedCarboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal CancerPralatrexate is a type of antifolate drug which means is restrains the production of folic acid in the body.NCT01188876·Boston, Massachusetts and 1 other

Active not recruitingStudy of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C).NCT04956640·Birmingham, Alabama and 48 others

TerminatedA Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerThe purpose of this study is to estimate the maximum tolerated doses (MTD) of CRLX101 when administered in combination with weekly paclitaxel in women with recurrent or…NCT02389985·Boston, Massachusetts and 6 others

CompletedSGI-110 in Combination With Carboplatin in Ovarian CancerA 2-part, Phase 2 controlled, open-label, randomized study in participants with platinum-resistant recurrent ovarian cancer.NCT01696032·Los Angeles, California and 23 others

UnknownStudy of T900607-Sodium in Previously Treated Patients With Ovarian Cancer.The purpose of this study is to determine whether T900607-sodium is effective and safe in treating ovarian cancer.NCT00043446·La Jolla, California and 4 others

TerminatedLiposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal CancerRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.NCT00003380·Birmingham, Alabama and 62 others

Active not recruitingTesting the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced CancerThis phase I trial studies the side effects and best dose of ziv-aflibercept when given together with pembrolizumab in treating patients with solid tumors that that may have…NCT02298959·Tampa, Florida and 8 others

Active not recruitingA Phase II Study Of Nivolumab/ Bevacizumab/RucaparibThis research study is evaluating three drugs called Nivolumab, Bevacizumab, and Rucaparib as a possible treatment for relapsed Relapsed Ovarian, Fallopian Tube Or Peritoneal…NCT02873962·Boston, Massachusetts and 2 others

CompletedINCB106385 Alone or in Combination With Immunotherapy in Advanced Solid TumorsThis is a multicenter, open-label, dose-escalation/dose-expansion Phase 1 clinical study to investigate the safety, tolerability, PK profile, pharmacodynamics, and preliminary…NCT04580485·West Hollywood, California and 26 others

TerminatedDurvalumab, Tremelimumab + Radiotherapy in Gynecologic CancerThis research study is evaluating the safety and effectiveness of 2 immunotherapy drugs in combination with radiation therapy as a possible treatment for recurrent or metastatic…NCT03277482·Boston, Massachusetts and 1 other

Active not recruitingSurgery in Preventing Ovarian Cancer in Patients With Genetic MutationsThis phase II trial studies how well surgery works in preventing ovarian cancer in patients with genetic mutations at risk of ovarian cancer.NCT02760849·Chicago, Illinois and 8 others

CompletedA Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian CancerThe purpose of this study is to evaluate the effect of BSI-201 on the objective response rate in platinum-sensitive recurrent ovarian cancer patients receiving gemcitabine and…NCT01033123·Boston, Massachusetts

CompletedA Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid TumorsThis is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-7909\] plus a mixture of…NCT04853017·Duarte, California and 9 others

Active not recruitingOlaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy.NCT01844986·Huntsville, Alabama and 176 others

RecruitingAZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian CancerThe intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade…NCT07218809·Birmingham, Alabama and 298 others

RecruitingSolid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell ManufacturingObjective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect…NCT04981119·Gilbert, Arizona and 15 others

PreviousPage 13 of 22Next

Other Conditions in Massachusetts

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia